NHS Dudley Health Economy Medicines Formulary
Home > 13 Skin > 13.5 Preparations for eczema and psoriasis > 13.5.3 Drugs affecting the immune response > Adalimumab for treating moderate to severe hidradenitis suppurativa - NICE TAG TA392

Adalimumab for treating moderate to severe hidradenitis suppurativa - NICE TAG TA392

1.1 Adalimumab is recommended, within its marketing authorisation, as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy. The drug is recommended only if the company provides it at the price agreed in the patient access scheme.

1.2 Assess the response to adalimumab after 12 weeks of treatment, and only continue if there is clear evidence of response, defined as:

  • a reduction of 25% or more in the total abscess and inflammatory nodule count and

  • no increase in abscesses and draining fistulas.

https://www.nice.org.uk/guidance/ta392

Site by Devopa
© Copyright 2020 NHS. All rights reserved.